MedTrace Logo

Ranibizumab Treatment for Retinal Vein Occlusion

NCT01968616 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-03-10

No results posted yet for this study

Summary

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Conditions

  • Macular Edema Due to BRVO/CRVO

Interventions

DRUG

Ranibizumab, 0.5mg, Intravitreal

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968616 on ClinicalTrials.gov